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Objectives: Whilst the cost-effectiveness of everolimus + exemestane (EVE+EXE) 
versus placebo + exemestane (PBO+EXE) in patients with ER+ HER2- metastatic 
breast cancer has been demonstrated elsewhere, this is the first analysis to assess 
the implications for health spending at a population level. MethOds: The model 
uses a cumulative cohort approach, allowing incident patients to enter the model 
each year over a five-year period. The incident population was based on several 
factors: (i) the female population aged > 15 years; (ii) the proportion of those women 
with advanced invasive breast cancer; (iii) the proportion who are post-menopausal; 
(iv) the proportion who are hormone receptor positive; (v) the proportion who are 
HER2-; (vi) the proportion with asymptomatic visceral disease, and (vii) the propor-
tion for whom hormonal therapy is appropriate. Finally, the cohort was filtered 
to show those who had previously relapsed or progressed on NSAI. ‘Per patient’ 
treatment and adverse event costs were generated based on treatment-specific 
progression-free survival curves, and multiplied by the number of patients expected 
to receive each treatment according to market share data and likely uptake rates. 
An incremental analysis was performed, where two scenarios were compared: (i) a 
world without EVE+EXE, and (ii) a world with EVE+EXE. Results: It is expected that 
a total of 1,052 patients will be eligible to receive EVE+EXE over a five-year period. 
In a ‘world without EVE+EXE’, the total five year cost was estimated as £1,652,904. 
Assuming an annual uptake rate of 10%, in a ‘world with EVE+EXE’ the total cost 
over the same period was expected to be £2,271,606. Therefore, the incremental cost 
associated with the introduction of EVE+EXE in England and Wales is £618,702 over 
five years. cOnclusiOns: EVE+EXE was associated with modest increased health 
care costs but has, separately, been demonstrated to lead to incremental health 
benefits compared with other treatments.
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Objectives: There is a dearth of published health economic evidence on stem cell 
(SC) mobilization that can be leveraged effectively for transplant center decision 
making. Our objective was to develop representative budget impact models (BIM) for 
key decision makers to estimate the total financial impact of adopting plerixafor for 
SC mobilization patients undergoing autologous peripheral stem cell transplanta-
tion (ASCT) for multiple myeloma and lymphoma. The BIMs were developed for EU5 
(France, Germany, Italy, Spain, UK) and United States (US). MethOds: Prior to BIM 
development, in-depth interviews were conducted in EU5 (n= 33) and US (n= 20), to 
determine the most influential decison maker(s) for choosing a mobilization regi-
men. The choice of inputs and outputs that are critical for the adoption of plerixafor 
at the hospital level, were determined. Additionally, the BIM was developed using 
inputs from published literature and market research. Results: Primary research 
revealed that the center director and treating physician are the most influential 
decision makers, while hospital administrators, transplant coordinators, pharmacy 
directors, and apheresis directors have a more limited role. There was consensus 
on inputs critical for assessment: clinical (drug/regimen utilization, apheresis days, 
and success/failure rates) and economic (mobilization costs; drug costs; apheresis 
cost and hospitalization costs). Model outputs include: first mobilization success 
and total mobilization budget impact. Interviews with clinical experts, and primary 
literature review determined that the relevant mobilization regimen comparators 
for the models are Granulocyte-Colony Stimulating Factor (G-CSF) alone, G-CSF and 
plerixafor, G-CSF and chemotherapy mobilization with cyclophosphamide and the 
triple regimen G-CSF, chemotherapy mobilization and plerixafor. cOnclusiOns: 
Conducting primary interviews with key stakeholders and using the latest clinical 
practice information for critical inputs/outputs is essential for developing a repre-
sentative model that is applicable to decison makers.
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Objectives: In the Basque Country (Spain), mammographies have been done in bien-
nial basis to women in their fifties and sixties since 1996. The main objective of this 
project was the evaluation of the impact of the Screening program in terms of costs 
and health in the Basque women population since 1996. MethOds: A discrete event 
simulation model was built to represent the natural history of breast cancer in women 
invited to the breast cancer screening program in the Basque Country. The disease 
progress was described in three main states (healthy, preclinical and clinical) in the 
model. We assumed all women would be diagnosed at the beginning of the clinical 
stage unless it had been diagnosed previously through the screening program. The data 
collected among the 15 years when the screening program was held allowed model’s 
validation. In order to compare the economic impact of these scenarios mammography 
and treatment costs – depending on the diseasestage at diagnosis – were included. The 
health impact assessment was based on quality adjusted life expectancy of cancer 
patients. Results: Since the screening program started working, 8,925 cancers were 
detected among 313,475 women who attended the screening which represents the 76% 
of the invited ones. 60% of the diagnosed cancers were detected through the screening 
program. All the mammographies carried out during the evaluated years costed 46 
million Euros. Each cancer detected in the screened scenario costs 29,581.06€ , in the 
based treatment effect for denosumab versus ZA to estimate the denosumab SRE 
rate. Total number of SREs, total SRE management medical cost, BTA drug cost, 
and total cost were calculated. The impact of denosumab per-member-per-month 
(PMPM) at increasing utilization rates was assessed by comparing to a scenario 
without denosumab, i.e., all patients received ZA and reported. Additionally, 
impact of annual increase in denosumab use was conducted. Results: A total 
of 63 PrCa patients with BM received BTA. In the scenario where all eligible patients 
receiving ZA, an annual total number of SREs was 120. An annual denosumab use 
of 20%, 35% or 45% resulted in 4.2%, 7.4%, and 9.5% reduction in total SREs and 
5.3%, 9.3%, and 11.9% reduction in medical costs of managing SREs, compared to 
all patients receiving ZA. The drug cost was partially offset by the reductions in 
the medical cost and the increase in total cost was minimal (1.2%-2.7%). The PMPM 
ranged $0.002-$0.005. Consecutive-year analysis showed $0.001 increase in PMPM 
with 10% denosumab utilization increase. cOnclusiOns: Due to superior efficacy 
of denosumab versus ZA in SRE prevention in PrCa patients with BM, increased 
denosumab use results in medical cost reduction in a US MCO. Overall, denosumab 
provides additional clinical value with limited budget impact.
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Objectives: Ipilimumab is the first drug to be licensed in Italy for the treatment 
of advanced melanoma in adults who have received prior therapy. This study 
aims to estimate the budget impact of ipilimumab in patients who live in the 
Veneto Region. MethOds: Our analysis was performed from the perspective 
of the Italian health care system. Two scenarios were analyzed: one with the 
optimization of vials and the other without. Only drug acquisition costs (meas-
ured in euro) were considered into the analysis. All costs were referred to year 
2013. Results: Based on the incidence and mortality rates of the last three 
years, a total of 80 adult patients were assumed to be elegible for the treatment 
in the Veneto Region. The cost per mg of ipilimumab was € 53,70: one 10 ml vial 
contains 50 mg of ipilimumab and one 40 ml vial contains 200 mg of ipilimumab. 
The recommended induction regimen is 3 mg/kg administered intravenously 
every 3 weeks for a total of 4 doses. The costs per patient of one year’s therapy 
with ipilimumab ranged from € 45.108 with vial optimization (considering 4-5 
patients infused at the same time - average weight 70 kg) to € 53.700 without. 
The Veneto Region identified a single center for the preparation/administration 
of treatment to minimize drug waste and to reduce the yearly treatment cost 
per patient, with a saving of € 8.592 per patient/year. Applied to whole elegible 
patients (average weight 70-75 kg), it allows to obtain savings up to € 430.000-
690.000 per year. cOnclusiOns: High prices for new cancer drugs are a growing 
concern to payers, given the large number of cancer drugs in development and 
the limited health care resources. Vial optimization may be an useful strategy 
to decrease waste, maximizing the use of health care resources and ensuring 
that eligible patients are treated.
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Objectives: To compare the budget requirements of utilizing epoetin alfa Hexal vs. 
darbepoetin alfa in the German health care system MethOds: Anemia is a com-
mon side effect observed in patients receiving myelosuppressive chemotherapy. The 
purpose of this pharmacoeconomic analysis was to evaluate the cost-effectiveness 
of the short-acting biosimilar ESAs epoetin-alfa Hexal (EA) 30,000 or 40,000 IU weekly 
(QW) versus long-acting erythropoiesis-stimulating agent (ESA) darbepoetin alfa 
(DA) 150 mcg weekly (QW) and 500 mcg once every 3 weeks (Q3W) for the treatment 
of CIA. A budget impact model was constructed employing a payer perspective, per 
patient plus 5 year time horizon. The treatment period considered was based on 12 
weeks and was aligned with routine chemotherapy regimen administration. Model 
inputs included: medical treatment, outcomes, and health care service utilization 
from published clinical studies and summary of product characteristics recom-
mendation. Effectiveness of therapeutic alternatives was determined by comparing 
hemoglobin maintenance rates. Initial treatment with biosimilar epoetin α 30,000 
IU or 40,000 IU per week has been shown to produce a similar Hb response. Costs 
included only drug acquisition costs and reflect 2013 data. The analysis was per-
formed from the perspective of the German health care system. Results: The 
average expected pharmaceutical costs per patient were € 4,843 for DA Q3W, € 4,383 
for DA QW and € 2,944 for EA 30,000IU QW, € 3,946 for EA 40,000IU QW. Cost-savings 
associated utilizing with utilizing Epoetin Alfa Hexal 30-40,000 are 11-49% to DA 
QW and were 23-64% relative to DA 3QW. cOnclusiOns: In the treatment of CIA 
among cancer patients in Germany, epoetin alfa Hexal is projected to provide more 
efficient use of health care resources compared to alternative treatment strategies 
with darbepoetin alfa.
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prices fixed by negociation between the Comité Economique des Produits de Santé 
and the manufacturers. The average discount ranges from 11% to 73%. The aver-
age EMI varies between 1.42 and 2.69 € excluding value added tax (EVAT) per 1000 
international units and between 0.09 and 0.22 € EVAT per microgram according 
to the medicinal product. The average amount refunded to HF can be estimated 
at january 1, 2012 at 3.37 M€ , or 22.6% of the total budget. We assessed annual 
prices trends based on starting dates of contract, and we could figure out EMI 
trends. According to the product, the EMI quickly decline, remain broadly stable 
or increase. cOnclusiOns: Many of top-selling biologics are due to lose patent 
protection over the next years. The emergence of competition in pharmaceutical 
market contributes to better control expenditure in our health system. The great 
potential for cost savings concerning erythropoietic factors in our study could be 
investigated in other class of medicinal products.
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Objectives: To assess the economic impact of Fentanyl Buccal Tablet for the 
management of breakthrough cancer pain (BTcP) in Spain MethOds: A 4-year 
budget impact model was developed for the period 2012-2015 for patients with 
BTcP from the perspective of the Spanish National Health System. BTcP products 
included in this model were rapid onset opioids containing fentanyl products 
(buccal, sublingual, or nasal transmucosal). Prevalence data on cancer, BTcP, opi-
oid use and number of BTcP episodes were obtained from literature. Input data 
on direct medical resources associated with opioid use and opioide-induced side 
effects (OISEs) were obtained by consulting experts in oncology from different 
Spanish hospitals. Resource utilisation included drugs, medical and emergency 
visits, other non-pharmacological treatments and the treatment of OISEs. Unit 
costs were obtained from literature and a 3% discount rate was applied to costs. 
Based on the unit costs for drugs and medical resources the annual BTcP treatment 
costs per patient associated with each product were determined, to estimate the 
overall budget impact based on the total treatment population and the percentage 
of drug utilisation associated with each product Results: Patients treated with 
oral opioids for BTcP was estimated at 23,291 in 2012 with an increase up to 23,413 
in 2015. The average annual budget savings with an increase of Fentanyl Buccal 
Tablet, Fentanyl Sublingual Tablet and Intranasal Fentanyl Spray and a decrease 
of Oral Transmucosal Fentanyl Citrate, was estimated at € 2.6 million over the 
next four years cOnclusiOns: The increase in the use of Fentanyl Buccal Tablet 
leads to overall savings in the budget impact for the Spanish NHS. Although the 
economic impact of BTcP treatment showed to increase over the next four years 
due to population growth the average annual cost per patient reduced with € 29 
by the increase in the use of Fentanyl Buccal Tablet.
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Objectives: To evaluate clinical and economic impact of increasing deno-
sumab use compared to zoledronic acid (ZA) in BrCa patients with BM to a 
MCO. MethOds: An economic model was developed to estimate clinical and 
economic impact to a 1-million-member US MCO of introducing denosumab as 
bone-targeting agent (BTA) for prevention of SREs in BrCa patients with BM. Total 
number of patients receiving BTA was estimated based on disease prevalence and 
treatment eligibility in this population. The real-world SRE rates in ZA-treated 
patients were derived from a large commercial database and used together with 
the trial-based treatment effect for denosumab versus ZA to estimate the deno-
sumab SRE rate. Total number of SREs, total SRE management medical cost, BTA 
drug cost, and total cost were calculated. The impact of denosumab per-member-
per-month (PMPM) at increasing utilization rates was assessed by comparing to 
a scenario without denosumab, i.e., all patients received ZA. Additionally, impact 
of annual increase in denosumab use was conducted. Results: A total of 122 
BrCa patients with BM received BTA. In the scenario where all eligible patients 
receiving ZA, an annual total number of SREs was 155. An annual denosumab use 
of 20%, 35% or 45% resulted in 4.5%, 7.9%, and 10.2% reduction in total SREs and 
5.7%, 10.1%, and 12.9% reduction in medical costs of managing SREs, compared to 
all patients receiving ZA. The drug cost was partially offset by the reductions in 
the medical cost and the increase in total cost was minimal (2.4%-5.5%). The PMPM 
ranged $0.008-$0.017. Consecutive-year analysis showed $0.004 increase in PMPM 
with 10% denosumab utilization increase. cOnclusiOns: Due to superior efficacy 
of denosumab versus ZA in SRE prevention in BrCa patients with BM, increased 
denosumab use results in medical cost reduction in a US MCO. Overall, denosumab 
provides additional clinical value with limited budget impact.
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Objectives: Obinutuzumab is the first, glycoengineered type II antibody dem-
onstrating increased Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and 
background scenario the cost was 29,639.22€ . In terms of total costs the background 
scenario had a lower cost on average until the year 2009. cOnclusiOns: Early detec-
tion of breast cancer improves survival prognosis and decreases treatment costs for 
each detected cancer. In the future, the costs of the early detection program will be 
balanced by the savings in treatment costs.
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Objectives: Metastatic prostate cancer (MPC) results from the spread of cancer to 
distant parts of the body and is associated with markedly decreased survival. First 
line therapy for prostate cancer involves androgen deprivation, however most MPC 
patients progress in spite of castration levels of testosterone. A recently approved 
infusion product, Radium Ra 223 dichloride (Radium-223), has been introduced in 
the U.S. market adding to concerns about the costs for end-stage treatments. We 
sought to estimate the budget impact of Radium-223 on infusion center expenses 
in the U.S. MethOds: We developed a financial model to estimate budget impact 
from a hospital-based infusion center perspective. Using data from the U.S. Census, 
SEER, and the Premier Perspective Database, we estimated the eligible population 
using a theoretical hospital’s catchment area. We modeled use, treatment costs 
and reimbursement for three radiopharmaceuticals (Radium-223, Samarium-153, 
and Strontium-89) and two common chemotherapies (docetaxel and cabazitazel) 
in terms of drug cost, infusions, and laboratory monitoring. Reimbursement for 
these treatments was estimated at both commercial and Medicare rates using the 
Average Sale Price and relevant Common Procedural Technology codes. We calcu-
lated total cost and reimbursement for one year with the current utilization from 
Premier and then estimated the incremental net budget impact associated with 
adoption of Radium-223 at 1, 3, and 5% of patients. Results: In a catchment area 
of 1 million lives, an estimated 45 MPC patients with non-visceral bone metastases 
would be treated with current agents and incur approximately $500,000 in treat-
ment costs for radiopharmaceuticals and chemotherapy. Adding Radium-223 to the 
treatment mix and assuming adoption rates of 1% to 5%, the annual net impact 
on the infusion center budget would range from $600 to $3,000. cOnclusiOns: 
Radium-223 presents a new treatment option for MPC patients with non-visceral 
bone metastases and a positive net impact for infusion centers.
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Objectives: Ovarian cancer (OC) is one of the most lethal gynecologic cancers 
worldwide. According to Brazilian Institute of Cancer (INCA), 6,190 new OC cases 
were estimated in 2012. During the last 15 years, carboplatin plus paclitaxel (CP) 
has been established as front-line (FL) standard of care therapy for advanced ovar-
ian cancer, with no significant advances in treatment ever since. Bevacizumab 
(Bev) in combination with CP was approved in Brazil for FL treatment of advanced 
epithelial OC on May/2013. Therefore, this study aimed to estimate the economic 
impact of bevacizumab reimbursement for advanced OC in Brazilian Supplementary 
Healthcare System. MethOds: The potential number of eligible patients for CP + 
Bev in FL therapy for advanced OC was estimated following an epidemiologic 
approach. It was assumed that Supplementary Healthcare System attendance 
accounts for 40% of all patients. Additional drug costs and infusion fees were evalu-
ated. The ex-factory price (VAT 18%) and labeled dose were considered. Average 
therapy duration of CP + bevacizumab was 15 months based on GOG-0218 trial. Costs 
were reported in Brazilian Reais (BRL1.00≈USD0.44; Jun/2013). A total health assis-
tance budget of BRL 88.1 billion was forecasted for 2013, based on the last updated 
data from Brazilian National Regulatory Agency for Private Health Insurance and 
Plans (ANS). Results: A total of 1,287 eligible cases in CP + Bev FL therapy for 
advanced OC are expected in 2013 in the private setting. Adding bevacizumab to 
the treatment of all these potential patients would yield an increase of BRL 267 
million, corresponding only to an increment around 0.30% on health assistance 
expenses. cOnclusiOns: Treating all eligible FL advanced OC patients with CP + 
Bev will potentially result in a low impact in Supplementary Healthcare System 
budget, associated to unprecedented clinical benefits for this population with a 
high medical unmet need.
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Objectives: The patent expiries of leading biologic products and development of 
biosimilars create opportunities for cost saving. The french public health policies 
has established a complementary means encouraging heathcare facilities (HF) to 
save money : the ‘‘écart médicament indemnisable’’ (EMI). We explored the evalu-
ation of EMI on the erythropoietic factors class. MethOds: We’ve carried out a 
comparative study in french HF, representing about 65% of national hospital beds, 
on the price of erythropoietic factors. The data have been collected on procurement 
procedures operative as at January 1, 2012. Results: A total of 25 care facilities or 
group of care facilities agreed to participate in the study. The overall sales turnover 
reached 15 millions euros (M€ ). All HF granted a discount from 5% to 69% on the 
